Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 11, 2010

Otonomy Secures $10M to Advance Therapeutics for Hearing and Balance Disorders

  • Otonomy completed a $10 million Series A financing with Avalon Ventures. The funding will be used to support ongoing clinical investigations of OTO-104 in Meniere disease, initiate IND-enabling studies for OTO-203, and continue early-stage development of a third program.

    OTO-104 is a sustained-release formulation of the steroid dexamethasone. Otonomy is conducting a prospective, randomized, placebo-controlled, multicenter Phase Ib study with OTO-104 given as a single intratympanic (IT) injection in subjects with unilateral Meniere disease. Preclinical studies have demonstrated that the compound can effectively deliver a prolonged and dose-proportional exposure of dexamethasone to the inner ear and is well-tolerated in a broad set of safety evaluations, according to the company.

    The firm is also planning studies with OTO-104 for acute hearing loss. OTO-203 is a sustained-release antibiotic being developed for the treatment of otitis media. Otonomy’s pipeline is focused on therapies for disorders of the inner and middle ear.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »